The ADMA chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ADMA chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The ADMA stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View ADMA Detailed Price Forecast - CNN Money||View ADMA Detailed Summary - Google Finance|
|View ADMA Detailed Summary - Yahoo! Finance||View ADMA Stock Research & Analysis - Zacks.com|
|View ADMA Trends & Analysis - Trade-Ideas||View ADMA Major Holders - Barrons|
|View ADMA Call Transcripts - NASDAQ||View ADMA Breaking News & Analysis - Seeking Alpha|
|View ADMA Annual Report - CompanySpotlight.com||View ADMA OTC Short Report - OTCShortReport.com|
|View ADMA Fundamentals - TradeKing||View ADMA SEC Filings - Bar Chart|
|View Historical Prices for ADMA - The WSJ||View Performance/Total Return for ADMA - Morningstar|
|View the Analyst Estimates for ADMA - MarketWatch||View the Earnings History for ADMA - CNBC|
|View the ADMA Earnings - StockMarketWatch||View ADMA Buy or Sell Recommendations - MacroAxis|
|View the ADMA Bullish Patterns - American Bulls||View ADMA Short Pain Metrics - ShortPainBot.com|
|View ADMA Stock Mentions - StockTwits||View ADMA Stock Mentions - PennyStockTweets|
|View ADMA Stock Mentions - Twitter||View ADMA Investment Forum News - Investor Hub|
|View ADMA Stock Mentions - Yahoo! Message Board||View ADMA Stock Mentions - Seeking Alpha|
|View Insider Transactions for ADMA - SECform4.com||View Insider Transactions for ADMA - Insider Cow|
|View ADMA Major Holdings Summary - CNBC||View Insider Disclosure for ADMA - OTC Markets|
|View Insider Transactions for ADMA - Yahoo! Finance||View Institutional Holdings for ADMA - NASDAQ|
|View ADMA Stock Insight & Charts - FinViz.com||View ADMA Investment Charts - StockCharts.com|
|View ADMA Stock Overview & Charts - BarChart||View ADMA User Generated Charts - Trading View|
Benzinga's Daily Biotech Pulse: vTv Swoons On Failed Alzheimer's Trial, Regenxbio Gets FDA Fast Track For RGX-111
Posted on Wednesday June 13, 2018
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on June 12) ABIOMED, Inc. (NASDAQ: ABMD ) AngioDynamics, Inc. (NASDAQ: ...
ADMA Biologics Announces Closing of $40M Public Offering
Posted on Tuesday June 12, 2018
RAMSEY, N.J. and BOCA RATON, Fla., June 12, 2018-- ADMA Biologics, Inc. announced today the closing of its previously announced underwritten public offering of 8,368,200 shares of its common stock at a ...
ADMA Biologics Announces Pricing of Public Offering of Common Stock
Posted on Friday June 08, 2018
ADMA Biologics, Inc. (ADMA) (“ADMA” or the “Company”) announced today the pricing of its previously announced underwritten public offering of 8,368,200 shares of its common stock at a public offering price of $4.78 per share, resulting in gross proceeds of approximately $40.0 million before deducting underwriting discounts and commissions and other estimated offering expenses. The offering is expected to close on June 12, 2018, subject to the satisfaction of customary closing conditions. The Company has also granted the underwriters a 30-day option to purchase up to 1,255,230 additional shares of common stock at the public offering price before deducting underwriting discounts and commissions. ADMA intends to use the net proceeds from this offering (i) for continued remediation and ongoing improvement and enhancements at its plasma fractionation facility located in Boca Raton, FL, (ii) to submit the Prior Approval Supplement for, and relaunch of, Bivigam®, (iii) to resubmit the Biologics License Application for its lead pipeline product candidate, RI-002, (iv) in connection with U.S. Food and Drug Administration approval of its third plasma collection facility, and (v) for general corporate purposes and other capital expenditures.
ADMA Biologics Announces Proposed Public Offering of Common Stock
Posted on Thursday June 07, 2018
ADMA Biologics, Inc. (ADMA) (“ADMA” or the “Company”) announced today that it has commenced an underwritten public offering of its common stock. The Company intends to grant the underwriters of the offering a 30-day option to purchase up to an additional 15 percent of the number of shares of common stock sold in connection with the offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Raymond James & Associates, Inc. is acting as the sole book-running manager of the proposed offering.